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ABSTRACT:
Busulfan, at a dose of 16 mg/kg, is widely used in combination with
cyclophosphamide as a conditioning regimen for patients under-
going bone marrow transplantation. Wide interindividual variation
in busulfan kinetics and rapid clearance of the drug have been
reported, especially in children. Some of the factors contributing to
interpatient variability have been identified. They include circadian
rhythms, age, disease, drug interaction, changes in hepatic func-
tion, and busulfan bioavailability. In this study, we demonstrate
that hepatic glutathione S-transferase (GST) activity correlates
negatively with busulfan maximum and minimum concentrations
(Pearson’s correlation r 5 20.74 and 20.77, respectively) and pos-
itively with busulfan clearance (Pearson’s correlation r 5 0.728) in
children with thalassemia major in the age range of 2 to 15 years.
We also found that plasma alpha GST levels were 5 to 10 times
higher in patients with thalassemia than in normal controls and
age-matched leukemic patients, either reflecting extensive liver
damage, elevated expression of the enzyme, or both in thalasse-
mic patients. Plasma alpha GST concentrations showed a similar
correlation with busulfan kinetic parameters to that observed for
hepatic GST. The status of hepatic GST activity accounts, at least
in part, for the observed interindividual variation in busulfan kinet-
ics, while the observed association with plasma alpha GST is
difficult to explain at present.
Busulfan is an alkylating agent that is used in combination with
cyclophosphamide as a myeloablative conditioning regimen for pa-
tients undergoing bone marrow transplantation (BMT1) for malignant
and nonmalignant disorders (Santos et al., 1983; Copelan et al., 1991;
Lucarelli et al., 1995). Busulfan is metabolized extensively in the liver
by glutathione S-transferase (GST)-mediated conjugation with gluta-
thione (Roberts and Warwick, 1961). Cytochrome P450 enzymes
seem not to be involved (Vassal et al., 1994). Alpha GST is found in
the human liver at high concentrations, accounting for 5% of total
soluble protein, and is mostly located in the pericentral regions (Hayes
and Pulford, 1991). Recent studies (Czerwinski et al., 1996; Gibbs et
al., 1996) have shown that all three known isoenzymes of GST (alpha,
mu, and pi) are involved in the conjugation of busulfan in the liver.
However, alpha GST is the principal catalyst of busulfan conjugation;
other isoforms contribute only to a minor extent and are probably
involved mainly in the protection of specific cells (Czerwinski et al.,
1996). The fourth class of GST, GST theta, is known to be active
toward 1,2-epoxy-3-(p-nitrophenoxy) propane or 1-menaphthyl sul-
fate. However, the role of GST theta on busulfan conjugation is not
yet known. A recent report by Gibbs et al. (1999) states that young
children show greater busulfan conjugating activity in intestinal bi-
opsies, which would most likely be due to enhanced GST alpha
expression. Hassan et al. (1991) suggested that the extensive interin-
dividual variability in busulfan kinetics observed in their study might
be due to the differences in levels of hepatic GSH or GST activity. We
have previously reported large differences in busulfan pharmacoki-
netics between children with beta thalassemia major undergoing BMT
(values differing by a factor of 2–12) (Poonkuzhali et al., 1999). We
also noted a significant decrease in busulfan Cl/F with increasing age
in this group (unpublished observations). Such a high degree of
interindividual variability led us to investigate the factors that may
affect busulfan metabolism. The aim of this study was to assess the
effect of GST and related enzymes on busulfan pharmacokinetics in
children with beta thalassemia major undergoing BMT.
Materials and Methods
Patients and Treatment. All children with beta thalassemia major under-
going BMT from human leukocyte antigen identical sibling donors at the
Christian Medical College Hospital, Vellore, India from September 1996 to
October 1998 were included in this study. Patients were randomly assigned to
two groups, A and B, conditioned as follows: regimen A, 16 mg/kg busulfan
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1 200 mg/kg cyclophosphamide 1 antithymocyte globulin; regimen B, 600
mg/m2 busulfan 1 200 mg/kg cyclophosphamide.
The characteristics of the patients are given in Table 1. Of the 39 total
patients, liver biopsy specimens were available for 37 patients, and samples for
alpha GST assay were available for 15 patients. Forty-six normal control
plasma samples (age range 18–30 years) were available for alpha GST assay.
Since the patients’ age range was 2 to 15 years, age-matched normal controls
were not available for comparison. Instead, plasma samples from 20 age-
matched patients with acute leukemias at first diagnosis (age range 2–15 years)
were available. Quantitative plasma alpha GST assay was carried out using
specific ELISA method as mentioned below.
Liver Biopsy Specimens. As part of the pretransplant evaluation, liver
biopsy specimens were taken from all thalassemic patients for histological
evaluation (approximately 2 weeks before BMT). An additional piece of tissue
was obtained for the analysis of GST activity. Informed consent was obtained
from the parents of all patients, and the entire study was approved by the
institutional review board. Liver tissues were stored frozen (for a maximum of
1 week) at 220°C until analysis. The time interval between the collection of
liver biopsy tissue and busulfan treatment ranged from 2 to 7 days.
Sonication of Liver Tissue. Liver tissue was allowed to thaw and was
transferred to 1 M phosphate buffer (pH 7.4) on ice (200 ml for approximately
5 mg wet weight of tissue). It was subjected to sonication in a Soniprep
sonicator (Sanyo Soniprep 150 MSE) at a temperature of 4 to 8°C. The
resulting suspension was then spun at low speed (400g) at 4°C for 5 min to
remove insoluble debris. All assays were performed immediately after soni-
cation.
GST activity [using CDNB (1-chloro-2,4-dinitro benzene) as substrate and
following the increase in absorbance at 340 nm] (Awasthi et al., 1991), total
glutathione levels (Owens et al., 1965), and glutathione reductase activity (Racker,
1955) in liver tissue homogenate were determined using methods described
elsewhere. All enzyme activities are expressed in units per milligram of protein
(specific activity). One unit of GST is the amount required to conjugate 1 mmol of
the substrate with glutathione in 1 min. One unit of glutathione reductase is the
amount of enzyme needed to convert 1 mmol of NADPH/min. Protein in the tissue
homogenates was determined by Lowry’s method (1951).
Sample Collection for ELISA. For the quantitative analysis of alpha GST,
plasma samples were collected and stored at 220°C until analysis. Samples were
collected from all normal controls and patients before the start of any treatment.
ELISA. The Hepkit ELISA kit (Biotrin International, Dublin, Ireland) was
used (with no modification of the manufacturer’s protocol) for the quantitative
analysis of alpha GST. Hepkit alpha is shown to be highly specific for the
detection of alpha GST. No significant cross reactivity is observed with either
mu or pi isoforms of GST as determined by enzyme immunoassay or immuno-
blot analysis (Manning et al., 1995).
Busulfan Assay and Pharmacokinetic Analysis. Busulfan in plasma sam-
ples was determined using a new HPLC method as described before (Quernin
et al., 1999). The limits of detection for the HPLC-UV method we used were
50 to 2000 ng/ml as compared with 20 to 2000 ng/ml for the gas chromatog-
raphy-mass spectrometry method (Quernin et al., 1998). The sensitivity of the
gas chromatography-mass spectrometry method using tetrafluorothiophenol
derivatization was 10 ng/ml, and the HPLC method using the same derivati-
zation was 20 ng/ml; the curve was linear up to a concentration of 2000 ng/ml.
The interday and intraday coefficients of variation were less than 3% for the
standards used to produce the calibration curve. Pharmacokinetic parameters
were calculated as described elsewhere (Poonkuzhali et al., 1999), using the
program Topfit (Gustav Fischer Verlag GmbH & Co., Stuttgart, Germany)
(Heinzel et al., 1991).
Statistical Analysis. All statistical comparisons were performed using
SPSS version 7.5 for Windows software (SPSS, Chicago, IL). Linear regres-
sion, step-wise multiple regression, Pearson’s correlation analysis, and Stu-
dent’s t test were used as appropriate.
Results
The linear regression curves for hepatic GST activity versus busul-
fan maximum concentration (Cmax in ng/ml), minimum concentration
FIG. 1. Linear regression curves for hepatic GST activity versus busulfan
pharmacokinetic parameters.
MRV, mean residual value.
TABLE 1
Patient characteristics and busulfan dosage
UPN Age Sex Weight BSA Bu Dose Risk Category*
kg m2 mg/kg
29 4 F 13.5 0.65 28.4 II
95 9 F 23 0.9 23.6 III
98 2 M 15 0.6 16 II
99 5 M 15 0.65 25.6 III
100 10 M 16 0.73 16 III
103 5.5 M 18 0.73 16 III
104 4 M 14 0.60 25.1 III
105 2.5 F 10.4 0.50 27.7 II
106 10 F 28 1.00 16 III
109 13 F 33 1.09 19.9 III
110 13 F 23.8 0.88 22 III
111 5 M 14.5 0.7 28.7 III
121 2.5 M 11.2 0.51 25.7 I
122 4.5 M 14.2 0.67 28.2 I
123 2.5 M 11.1 0.55 29 II
124 4.5 M 14 0.60 16 II
125 2 F 11.3 0.52 27 I
128 12 M 25 0.96 16 III
131 5.5 F 15 0.70 16 III
133 13 M 29 1.05 16 III
134 3 M 12 0.74 16 II
136 7 F 20 0.80 16 III
139 5 F 20 0.84 16 II
140 11 M 25.3 0.95 22.7 III
142 10 M 18 0.80 16 III
143 7 M 20 0.82 24 III
144 14 M 32 1.20 16 III
151 5.5 M 15 0.62 24.5 II
157 6.5 F 19 0.84 26 III
159 15 F 26 1.12 14 III
160 13 M 30 1.10 16 III
161 3.3 M 11 0.52 29 II
162 11 F 34 1.10 16 III
163 11 M 20 0.80 16 III
165 5 F 20 0.80 16 III
166 6 F 11 0.50 16 II
167 12 M 26.9 1.00 22.6 III
168 6 F 18 0.73 24.4 II
170 5 M 17 0.66 16 III
UPN, unique patient number; Bu, busulfan.
* Risk category as per Lucarelli et al. (1990).
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(Cmin in ng/ml), clearance (Cl/F in l/h/kg), and area under the con-
centration versus time curve (AUC in ngzh/ml) are shown in Fig. 1.
Significant negative correlations were found between busulfan Cmax,
Cmin, and AUC and hepatic GST activity. There was also a similar
correlation between these kinetic parameters and total GSH levels,
although less significant. A significant positive correlation was found
between busulfan Cl/F and total liver GST activity. Similar correlation
between plasma alpha GST and busulfan kinetic parameters was also
observed (Table 2). The correlation between plasma GST versus
busulfan Cl/F is shown in Fig. 2. There was no significant correlation
between glutathione reductase activity and any of the busulfan kinetic
parameters. Overall, age and hepatic GST activity showed a signifi-
cant negative correlation of 20.594 (p , 0.01). Hepatic GST activity
and GSH levels showed a correlation of 0.324 (p , 0.01).
Step-wise multiple regression analysis was done with hepatic GST
activity and hepatic GSH levels as possible predictors of busulfan
Cl/F. In the model in which GSH entered the analysis first, there was
a statistically significant improvement when hepatic GST was added
to the model (r2 change 5 0.336, p , 0.001). When hepatic GST
entered the analysis first, there was no additional improvement in the
model with the addition of GSH levels (r2 change 5 0.096, p 5 0.02).
When we included plasma alpha GST also in the step-wise multiple
regression analysis, in the model where alpha GST entered the anal-
ysis first, addition of hepatic GST improved the prediction of busulfan
Cl/F significantly (r2 change 5 0.331, p 5 0.001).
We determined plasma alpha GST concentration and its relative
distribution in normal controls (3.8 6 0.525 mg/l), age-matched
leukemic (4.5 6 0.585 mg/l), and thalassemic patients (29.03 6 11.1
mg/l) (Table 3). We compared hepatic and plasma alpha GST con-
centration in thalassemic patients by Pearson’s correlation analysis
(r 5 0.751) (Fig. 2). Patients with high hepatic GST activity also had
high plasma alpha GST concentration. Plasma alpha GST concentra-
tion in class II and class III patients were compared using two-tailed
Student’s t test. Class III patients had higher plasma alpha GST
concentration than class II patients (31.5 versus 21.6 mg/l), but the
difference was not statistically significant (p 5 0.14).
Discussion
The metabolism of busulfan has been extensively studied in animal
models (Roberts and Warwick, 1961; Vassal et al., 1994). Recent studies
have shown that busulfan is metabolized in the liver by the GST (alpha,
mu, and pi) enzymes (Czerwinski et al., 1996; Gibbs et al., 1996), alpha
contributing to a major extent. There is no study so far reporting the role
of GST theta on busulfan conjugation. Gibbs et al. (1996, 1997b) have
shown in in vitro incubation with liver and intestinal cytosols that GST
A1–1 is the major form involved in conjugation with busulfan in the liver
and intestines. The age dependence in busulfan clearance was reported to
be due to the age-dependent tetrahydrothiophene formation (Gibbs et al.,
1997a) which in turn is caused by the up-regulated expression of this
enzyme in young children. Recently Gibbs et al. (1999) have reported
that the elevated GSH conjugation of busulfan in intestinal biopsy spec-
imens of young children suggests that the difference in clearance is due
to up-regulated busulfan-GSH conjugation in these children. These au-
thors have stated that the possibility that GST alpha expression is up-
regulated in liver of young children has not yet been assessed. The
present study, although not directly showing the up-regulation of hepatic
GST in these children, is the first report to show a correlation between
hepatic GST activity with busulfan clearance and plasma levels. We
TABLE 2
Correlation of hepatic and plasma glutathione S-transferase with busulfan kinetic
parameters
Hepatic GST in units/mg of protein, Hepatic GSH in nmol/mg of protein, and plasma
alpha GST in mg/l.
mAUC m Cl/F m Cmax MRV m Cmin
Hepatic GST
r2 value 20.633 0.63 20.68 0.69 0.7
P value 0.01 0.01 0.01 0.01 0.01
Pearson’s r 20.80 0.728 20.74 20.64 20.77
Hepatic GSH
r2 value 20.248 0.28 0.09 0.17 0.12
P value 0.01 0.01 N.S. 0.05 0.05
Pearson’s r 20.492 0.532 20.31 20.417 20.35
Plasma alpha GST
r2 value 20.53 0.566 20.42 20.344 20.53
Pearson’s r 20.70 0.751 20.68 20.55 20.73
P value 0.01 0.01 0.01 0.05 0.01
m, mean; MRV, mean residual value; Pearson’s r, correlation coefficient by Pearson’s
analysis; r2 value, linear regression coefficient.
FIG. 2. Linear regression curves for plasma alpha GST levels versus busulfan
mean Cl/F (A) and hepatic GST activity (B).
TABLE 3
Plasma alpha GST levels in thalassemic children, leukemic children, and
controls
Plasma alpha GST levels of thalassemic children were significantly higher than normal
controls (p 5 0.001) and age-matched leukemic children (p 5 0.001) when analyzed by
Mann-Whitney U test.
Thalassemic
Children
Leukemic
Children Controls
Age range (yr) 2–15 2–15 18–30
n 16 20 48
Alpha GST levels (mg/l)
(mean 6 S.D.)
29.03 6 11.1 4.5 6 0.585 3.8 6 0.525
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found a negative correlation between total GST activity and total GSH
levels in the liver and the plasma concentration of busulfan in this study.
This shows that busulfan pharmacokinetics in children with thalassemia
are significantly influenced by hepatic GST activity. Variations in hepatic
GST activity may account at least in part for the interindividual variability
in the pharmacokinetics of busulfan.
There was a positive correlation of busulfan Cl/F and GST activity in
this study, consistent with GST being involved in busulfan metabolism.
The significant correlation between total hepatic GST activity with age
(Pearson’s r 5 20.594, p , 0.01**) may account for the differences in
busulfan clearance with age that we have observed in children with
thalassemia (unpublished observations). Hassan et al. (1991) suggested
that the shorter elimination half-life of busulfan in young children may be
attributed to higher levels of GSH or GST such as those occurring in
premature infants and neonates. Gibbs et al. (1997a) reported that tetra-
hydrothiophenium ion (the major metabolite of busulfan) formation in
young children and adults is age-dependent. Children had 1.5 times
greater area ratios for AUC [tetrahydrothiophene]/AUC [busulfan] (0–6
h) than adults, demonstrating greater capacity to metabolize busulfan by
glutathione conjugation. This study confirms that hepatic GST activity,
which is age-dependent, has an effect on busulfan clearance.
Recent studies (Czerwinski et al., 1996; Gibbs et al., 1996) have
evaluated the role of GST isoenzymes in the conjugation of busulfan
and have shown that alpha GST is the major isoform catalyzing this
conjugation reaction, whereas the other forms (mu, pi, and theta) may
be involved in the protection of specific cells, including hepatocytes,
placenta cells, and erythrocytes. We found a significant negative
correlation between plasma alpha GST levels and busulfan Cmax and
Cmin and significant positive correlation between plasma alpha GST
levels and busulfan Cl/F in this study, although the underlying reason
for this association is difficult to explain at present. It has already been
reported that 80% of busulfan conjugation is catalyzed by alpha GST
(Gibbs et al., 1996). The observed association suggests that plasma
alpha GST levels may help to predict the extent of busulfan metab-
olism in children with beta thalassemia major undergoing BMT.
Further studies are warranted to prove this hypothesis.
In our study, children with thalassemia had approximately 10-fold
higher plasma alpha GST concentrations than normal individuals (age
range 18–30 years) and age-matched leukemics (29.03 1 11.1 versus
3.8 1 0.525 and 4.5 1 0.585 mg/l; p 5 0.001), respectively. This may
be explained by the fact that plasma alpha GST levels increase when
there is acute (Mulder et al., 1996) or chronic liver damage (Mulder
et al., 1997). Beta thalassemia major is associated with varying
degrees of liver damage, which may contribute to the elevated plasma
alpha GST levels in these patients. The very high plasma alpha GST
levels in thalassemic patients in this study might reflect either exten-
sive liver damage, elevated expression of the enzyme per se, or both.
Previous studies have established that alpha GST is a uniquely spe-
cific and sensitive marker of damage to hepatocytes (Trull et al., 1994;
Nelson et al., 1995; Vaubourdolle et al., 1995). Its rapid release into
and removal from the circulation provides more immediate informa-
tion about liver status than other conventional aminotransferase mark-
ers (Mulder et al., 1997). Recently, alpha GST levels in the plasma
and liver tissues of healthy organ donors have been reported (Mulder
et al., 1999). This study is the first to report alpha GST levels in
children with beta thalassemia major.
The correlation between total hepatic GST activity with plasma
alpha GST concentration in thalassemic patients in this study suggests
a possibility of plasma alpha GST as one of the markers or probable
determinants of busulfan metabolism in this group of patients; how-
ever, further studies are needed to confirm this hypothesis.
The higher mean plasma alpha GST levels in class III than class II
patients (31.5 mg/l in class III versus 21.6 mg/l in class II), although
not statistically significant, confirm that this can be a good marker of
liver status in patients with thalassemia major.
The correlation of hepatic GST activity and plasma alpha GST
levels with busulfan kinetic parameters reported in this study offers
one explanation for the large interindividual differences in busulfan
metabolism observed in children with thalassemia major.
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